Ponatinib Submitted by Ariad Pharmaceuticals on 12/21/2012

Erwinia Asparaginase Submitted by SMT, Inc. on 04/05/2013

Glucarpidase Submitted by BTG International on 05/03/2013

Ponatinib Submitted by Ariad Pharmaceuticals on 01/15/2014

ClonoSIGHT™ MRD test Submitted by Sequenta, Inc. on 10/15/2014

Blinatumomab Submitted by Amgen, Inc. on 10/03/2016

Multiplex PCR and high throughput sequencing (HTS) platform Submitted by Adaptive Biotechnologies on 12/09/2016

Ponatinib Submitted by ARIAD Pharmaceuticals Inc on 12/19/2016

Blinatumomab Submitted by Amgen, Inc. on 03/20/2017

Inotuzumab ozogamicin Submitted by Pfizer Inc. on 08/17/2017

Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 08/31/2017

Blinatumomab Submitted by Amgen Inc. on 09/18/2017

Ibrutinib Submitted by Pharmacyclics, LLC on 09/29/2017

Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/15/2017

Inotuzumab Submitted by Pfizer Inc. on 01/24/2018

Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 03/29/2018

Hypercvad rituximab Submitted by Oregon Society of Medical Oncology on 08/08/2018

clonoSEQ® Submitted by Adaptive Biotechnologies Corporation on 09/13/2018

Glucarpidase Submitted by BTG International Inc. on 09/24/2018

clonoSEQ® Submitted by Adaptive Biotechnologies Corporation on 09/28/2018

Dasatinib Submitted by Bristol-Myers Squibb Company on 01/03/2019

Minimal (measurable) Residual Disease (MRD) Submitted by Adaptive Biotechnologies Corporation on 09/13/2019

clonoSEQ Submitted by Adaptive Biotechnologies on 10/27/2020

Blinatumomab Submitted by Amgen, Inc. on 12/10/2020

Sorafenib Submitted by Onyx Pharmaceuticals on 04/08/2014

Isocitrate dehydrogenase (IDH) testing Submitted by Celgene Corporation on 07/14/2016

Midostaurin Submitted by Novartis Pharmaceuticals Corporation on 05/02/2017

Next-Generation Sequencing (NGS) Submitted by Illumina Inc. on 06/26/2017

Isocitrate dehydrogenase-2 (IDH-2) testing Submitted by Celgene Corporation on 08/02/2017

Enasidenib Submitted by Celgene Corporation on 08/02/2017

Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 08/07/2017

Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 09/08/2017

Ibrutinib Submitted by Pharmacyclics LLC on 09/29/2017

Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 10/03/2017

Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 10/12/2017

Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/15/2017

Gilteritinib Submitted by Astellas Pharma Inc. on 04/13/2018

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Submitted by Stemline Therapeutics, Inc on 04/20/2018

Ivosidenib Submitted by Agios Pharmaceuticals, Inc on 04/23/2018

Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 04/27/2018

Venetoclax Submitted by AbbVie Inc. on 07/12/2018

Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals on 11/05/2018

Venetoclax Submitted by AbbVie Inc. on 11/21/2018

Tagraxofusp Submitted by Stemline Therapeutics on 12/13/2018

Gilteritinib Submitted by Astellas Pharma Inc. on 01/18/2019

Liposomal Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 03/07/2019

Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 03/14/2019

Venetoclax Submitted by AbbVie Inc. on 03/21/2019

Ivosidenib Submitted by Agios Pharmaceuticals, Inc on 04/02/2019

Quizartinib Submitted by Daiichi Sankyo, Inc. on 04/19/2019

Gemtuzumab Ozogamicin Submitted by Pfizer Inc. on 04/22/2019

Tagraxofusp Submitted by Stemline Therapeutics, Inc. on 04/24/2019

Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals on 04/26/2019

Gilterltinib Submitted by Astellas Pharma Inc. on 06/05/2019

Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 05/01/2020

Venetoclax Submitted by AbbVie Inc. on 06/26/2020

CC-486 Submitted by Bristol-Myers Squibb Company on 07/07/2020

Venetoclax + HMAs Submitted by AbbVie Inc. on 08/14/2020

Azacitidine Submitted by Bristol-Myers Squibb Company on 09/01/2020

Magnetic resonance-guided focused ultrasound Submitted by Insightec on 09/12/2016

Interventional radiology Submitted by Society of Interventional Oncology on 09/16/2019

Polymerized Cross-linked Sucralfate Submitted by MMI Script Hub and Medical Supplies on 06/18/2020

Algorithm & Discussion Changes Submitted by Society of Interventional Oncology on 08/11/2020

Granisetron Transdermal System Submitted by ProStrakan on 09/25/2014

Aprepitant Submitted by Merck & Co., Inc. on 09/10/2015

Granisetron Injection Submitted by Heron Therapeutics, Inc. on 09/15/2015

Rolapitant Submitted by TESARO, Inc. on 09/21/2015

Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 10/22/2015

Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 02/12/2016

Rolapitant Submitted by Tesaro, Inc. on 06/17/2016

Granisetron Submitted by Heron Therapeutics, Inc. on 08/10/2016

Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 10/17/2016

Carboplatin Submitted by Oncology Analytics, Inc. on 05/17/2017

Dronabinol Submitted by INSYS Therapeutics, Inc. on 08/11/2017

Granisetron Submitted by Heron Therapeutics, Inc. on 09/06/2017

Rolapitant Submitted by TESARO, Inc. on 10/20/2017

Aprepitant Submitted by Heron Therapeutics, Inc. on 11/15/2017

Fosnetupitant and Palonosetron Submitted by Helsinn Healthcare SA on 05/18/2018

Lenvatinib Submitted by Eisai Inc. on 04/21/2020

Vitamin D-25OH and bone mineral density testing Submitted by Aurora Health Care on 04/07/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/11/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Rituximab and hyaluronidase Submitted by Genentech, Inc. on 06/23/2017

Ibrutinib Submitted by Pharmacyclics LLC on 08/02/2017

Ibrutinib Submitted by Pharmacyclics LLC on 08/02/2017

Copanlisib Submitted by Bayer Healthcare Pharmaceuticals on 09/15/2017

Obinituzumab Submitted by Genentech, Inc. on 10/11/2017

Copanlisib modification Submitted by Bayer Healthcare Pharmaceuticals on 10/18/2017

Copanlisib Submitted by Bayer Healthcare Pharmaceuticals on 10/18/2017

Axicabtagene ciloleucel Submitted by Kite on 10/20/2017

Acalabrutinib Submitted by AstraZeneca on 11/01/2017

Defibrotide Submitted by Jazz Pharmaceuticals on 11/27/2017

Ibrutinib Submitted by Pharmacyclics LLC on 12/21/2017

Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 05/02/2018

Lenalidomide + Rituximab Submitted by Celgene Corporation on 06/03/2018

Next-generation sequencing Submitted by Adaptive Biotechnologies on 07/18/2018

Lenalidomide + Rituximab Submitted by Celgene Corporation on 08/07/2018

Duvelisib Submitted by Verastem, Inc. on 09/25/2018

Lenalidomide + Rituximab Submitted by Celgene Corporation on 12/03/2018

Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 12/06/2018

Lenalidomide + Rituximab Submitted by Celgene Corporation on 03/22/2019

Lenalidomide + Rituximab Submitted by Celgene Corporation on 05/28/2019

Polatuzumab vedotin Submitted by Genentech, Inc. on 06/10/2019

Siltuximab Submitted by EUSA Pharma, Inc. on 08/01/2019

Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 08/01/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 08/09/2019

Zanubrutinib Submitted by BeiGene, Ltd. on 11/14/2019

Polatuzumab Vedotin Submitted by Genentech, Inc. on 12/17/2019

Ibrutinib Submitted by Pharmacyclics LLC on 12/19/2019

2 Gy x 2 fractions Submitted by Oncology Analytics, Inc. on 02/08/2020

Zanubrutinib Submitted by BeiGene, Ltd. on 04/17/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Tazemetostat Submitted by Epizyme Inc. on 06/18/2020

Selinexor Submitted by Karyopharm Therapeutics on 06/23/2020

Brexucabtagene Autoleucel Submitted by Kite on 07/24/2020

Tafasitamab-cxix in combo with Lenalidomide Submitted by MorphoSys US Inc. and Incyte Corporation on 08/03/2020

NGS clarification Submitted by Adaptive Biotechnologies Corporation on 09/01/2020

Siltuximab Submitted by Castleman Disease Collaborative Network (CDCN) on 09/08/2020

Axicabtagene ciloleucel Submitted by Kite on 09/18/2020

Axicabtagene ciloleucel Submitted by Kite on 12/08/2020

Lisocabtagene maraleucel Submitted by Bristol Myers Squibb on 02/08/2021

Umbralisib Submitted by TG Therapeutics, Inc on 02/09/2021

Umbralisib Submitted by TG Therapeutics, Inc on 02/10/2021

Loncastuximab tesirine‐lpyl Submitted by ADC Therapeutics on 04/23/2021

Albumin-bound paclitaxel Submitted by Celgene on 03/07/2014

Eribulin Mesylate Submitted by Eisai, Inc. on 07/07/2015

Radiation Therapy Submitted by American Society for Radiation Oncology on 09/10/2015

Radiation Therapy Submitted by American Society for Radiation Oncology on 09/10/2015

Atezolizumab Submitted by Genentech, Inc. on 05/18/2016

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2016

Atezolizumab Submitted by Genentech, Inc. on 08/21/2016

Nivolumab Submitted by Bristol-Myers Squibb Company on 10/10/2016

Nivolumab Submitted by Bristol-Myers Squibb Company on 02/03/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 02/20/2017

Atezolizumab Submitted by Genentech, Inc. on 04/17/2017

Durvalumab Submitted by AstraZeneca on 05/02/2017

Avelumab Submitted by EMD Serono, Inc. on 05/09/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/19/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Csbladder Assays Submitted by Pacific Edge Diagnostics USA, Ltd. on 07/31/2017

Atezolizumab Submitted by Genentech, Inc. on 08/23/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Atezolizumab Submitted by Genentech, Inc. on 06/20/2018

Cystoscopy Submitted by Photocure, Inc. on 08/07/2018

Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018

Cxbladder Monitor Assay Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/31/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 10/23/2018

Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 04/15/2019

Atezolizumab Submitted by Genentech, Inc. on 06/18/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 07/09/2019

Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 07/30/2019

Genetic Alterations Submitted by Foundation Medicine, Inc. on 08/26/2019

Atezolizumab Submitted by Genentech, Inc. on 08/27/2019

Enfortumab vedotin Submitted by Seattle Genetics, Inc. on 12/06/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 01/08/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/30/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Avelumab Submitted by Pfizer Inc./EMD Serono, Inc. on 06/30/2020

Patient Advocate Recommendations Submitted by Bladder Cancer Advocacy Network (BCAN) on 07/27/2020

Urothelial tumor markers Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/13/2020

Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/28/2020

Avelumab Submitted by Pfizer Inc./EMD Serono, Inc. on 09/18/2020

Enfortumab vedotin Submitted by Seagen Inc./Astellas Pharma Global Development, Inc. on 02/16/2021

Atezolizumab Submitted by Genentech, Inc. on 03/08/2021

Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/15/2021

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Cabozantinib Submitted by Exelixis, Inc. on 04/12/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Glucarpidase Submitted by BTG International Inc. on 12/18/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/30/2020

Cabozantinib Submitted by Exelixis, Inc. on 04/15/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020

Bevacizumab Submitted by Genentech on 06/25/2010

Eribulin Submitted by Eisai on 11/17/2010

Denosumab Submitted by Amgen on 12/21/2010

Zoledronic Acid Submitted by Novartis Pharmaceuticals Corporation on 05/09/2011

Everolimus Submitted by Novartis Pharmaceuticals Corporation on 10/10/2011

Pertuzumab Submitted by Genentech on 06/01/2012

Ado-Trastuzumab Emtansine Submitted by Genentech on 02/22/2013

Toremifene Citrate Submitted by ProStrakan, Inc on 05/17/2013

Everolimus Submitted by Novartis on 06/26/2013

Breast-Specific Gamma Imaging (BSGI) Submitted by Dilon Technologies on 06/27/2013

Pertuzumab Submitted by Genentech on 07/01/2013

Pertuzumab Submitted by Genentech on 10/01/2013

Fluoropyrimidine Submitted by Ken Surprenant on 04/06/2014

Everolimus Submitted by Novartis on 04/23/2014

Breast Cancer Index (BCI) Submitted by bioTheranostics on 06/10/2014

Toremifene Submitted by ProStrakan on 06/17/2014

Toremifene Submitted by ProStrakan on 06/17/2014

CELLSEARCH Circulating Tumor Cell Test Submitted by Janssen Diagnostics on 06/20/2014

Prosigna Breast Cancer Gene Signature Assay Submitted by Nanostring Technologies on 06/20/2014

L-Dex U400 Submitted by ImpediMed, Inc on 06/23/2014

HERmark Submitted by LabCorp on 06/27/2014

Oncotype DX Breast Cancer Assay Submitted by Genomic Health on 06/27/2014

HER-2 Blood Test Submitted by Nuclea Diagnostic Laboratories on 06/27/2014

Everolimus Submitted by Novartis on 06/30/2014

Tamoxifen Submitted by DARA BioSciences, Inc. on 06/30/2014

Ado-Trastuzumab Emtansine Submitted by Genentech on 08/08/2014

Pertuzumab/Trastuzumab Submitted by Genentech on 11/06/2014

Everolimus Submitted by Novartis on 12/18/2014

Palbociclib Submitted by Pfizer Inc. on 06/02/2015

Breast Cancer Index (BCI) Submitted by bioTheranostics, Inc. on 06/12/2015

Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/19/2015

Pertuzumab/Trastuzumab Submitted by Genentech on 06/29/2015

Denosumab Submitted by Amgen on 07/13/2015

Zoledronic Acid Submitted by Sylvester Comprehensive Cancer Center/University of Miami Hospital and Clinics on 01/15/2016

Denosumab Submitted by Amgen, Inc. on 03/25/2016

Palbociclib Submitted by Pfizer Inc. Oncology on 04/26/2016

Albumin-bound paclitaxel Submitted by Celgene Corporation on 04/28/2016

Preoperative HER2-targeted therapy Submitted by Genentech, Inc. on 05/09/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 05/13/2016

Albumin-bound paclitaxel Submitted by Celgene Corporation on 06/07/2016

Breast Cancer Index (BCI) test Submitted by Biotheranostics, Inc. on 06/14/2016

Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/14/2016

Oncotype DX® Invasive Breast Cancer Assay Submitted by Genomic Health Inc. on 06/17/2016

Oncotype DX® Breast Cancer Assay Submitted by Genomic Health Inc. on 06/17/2016

Biomarker assay Submitted by Myriad Genetic Laboratories, Inc. on 06/20/2016

Everolimus Submitted by Novartis Pharmaceuticals Corporation on 06/20/2016

Albumin-bound paclitaxel Submitted by Celgene Corporation on 01/13/2017

Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 03/13/2017

Palbociclib Submitted by Pfizer Inc. on 04/03/2017

Recommend clarification on the locoregional recurrence section Submitted by American Society for Radiation Oncology (ASTRO) on 05/25/2017

70 gene MammaPrint assay Submitted by Agendia, Inc. on 05/26/2017

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Pertuzumab/Trastuzumab Submitted by Genentech, Inc. on 06/12/2017

Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/23/2017

Docetaxel Submitted by Hadassah-Hebrew University Medical Center on 06/30/2017

Goserelin Submitted by TerSera Therapeutics on 07/03/2017

70 gene MammaPrint assay Submitted by Agendia, Inc. on 07/03/2017

Bioimpedance spectroscopy Submitted by ImpediMed, Inc. on 07/10/2017

Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/10/2017

Oncotype DX® Breast Recurrence Score™ (RS) assay Submitted by Genomic Health, Inc. on 07/10/2017

Oncotype DX® Breast Recurrence Score™ (RS) assay Submitted by Genomic Health, Inc. on 07/10/2017

12-gene recurrence test Submitted by Myriad Genetic Laboratories, Inc. on 07/11/2017

Comprehensive genomic profiling (CGP) assays Submitted by Foundation Medicine, Inc. on 07/14/2017

Neratinib Submitted by Puma Biotechnology, Inc. on 07/17/2017

Everolimus Submitted by Novartis Pharmaceuticals Corporation on 07/19/2017

Fulvestrant Submitted by AstraZeneca on 08/28/2017

Abemaciclib Submitted by Eli Lilly and Company on 09/28/2017

Olaparib Submitted by AstraZeneca on 11/14/2017

Fulvestrant Submitted by AstraZeneca on 11/15/2017

Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 12/06/2017

Neratinib Submitted by Puma Biotechnology, Inc. on 12/28/2017

Comprehensive genetic testing Submitted by Illumina Inc. on 02/08/2018

Abemaciclib Submitted by Eli Lilly and Company on 02/26/2018

Tamoxifen Submitted by Sanford Health Pharmacogenomics Committee on 02/28/2018

Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 06/12/2018

Ribociclib + Fulvestrant Submitted by AstraZeneca on 06/28/2018

Ribociclib + Fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 06/29/2018

Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/03/2018

Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018

Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018

Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018

Next-generation sequencing (NGS) Submitted by Foundation Medicine, Inc. on 07/03/2018

Radiofrequency spectroscopy Submitted by Dune Medical, Inc. on 07/05/2018

EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018

EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018

Talazoparib Submitted by Pfizer Inc. on 10/16/2018

Atezolizumab Submitted by Genentech, Inc. on 10/20/2018

Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 12/05/2018

Neratinib Submitted by Puma Biotechnology, Inc. on 12/21/2018

Genetic Testing Guidelines Submitted by Targeted Medical Education (TME) on 02/18/2019

Trastuzumab and Hyaluronidase-oysk Submitted by Genentech, Inc. on 02/28/2019

Atezolizumab Submitted by Genentech, Inc. on 03/08/2019

Alpelisib Submitted by Novartis Pharmaceuticals Corporation on 05/24/2019

Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 05/28/2019

Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2019

Neratinib Submitted by Puma Biotechnology, Inc. on 06/10/2019

Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 06/10/2019

Locoregional therapies Submitted by Society of Interventional Oncology on 06/14/2019

Trastuzumab-dkst Submitted by Mylan N.V. on 06/26/2019

Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/15/2019

Trastuzumab-anns Submitted by Amgen Inc. on 07/19/2019

Subclinical Lymphedema Submitted by Vanderbilt University School of Nursing on 07/19/2019

EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019

EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019

Genomic Assays Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019

Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd. on 07/24/2019

Atezolizumab, Pertuzumab, Ado-trastuzumab Emtansine Submitted by Genentech, Inc. on 07/24/2019

Next-Generation Sequencing Assays Submitted by Foundation Medicine, Inc. on 07/24/2019

Breast Cancer Index (BCI) Submitted by Biotheranostics, Inc. on 07/25/2019

Denosumab Submitted by My Style Matters on 07/25/2019

Ixabepilone + Capecitabine Submitted by R-Pharm US on 07/30/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 09/29/2019

Abemaciclib Submitted by Eli Lilly and Company on 10/29/2019

Tucatinib Submitted by Seattle Genetics Inc. on 12/24/2019

Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc., and AstraZeneca Pharmaceuticals LP on 01/02/2020

EndoPredict Submitted by Myriad Genetics Laboratories Inc. on 01/27/2020

Estrogen receptor alpha-36 testing Submitted by Christina Rosati on 02/25/2020

Neratinib + capecitabine Submitted by Puma Biotechnology, Inc. on 02/27/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/18/2020

Tucatinib Submitted by Seattle Genetics, Inc. on 04/17/2020

Sacituzumab govitecan-hziy Submitted by Immunomedics, Inc. on 04/22/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Alpelisib + fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 05/12/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

TMB testing Submitted by Foundation Medicine, Inc. on 06/22/2020

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Submitted by Genentech, Inc. on 06/29/2020

Ado-trastuzumab emtansine Submitted by Linda W. Wilson, MD on 07/08/2020

Radiation Therapy Submitted by American Society for Radiation Oncology (ASTRO) on 07/20/2020

21-Gene RT-PCR assay Submitted by Exact Sciences on 07/28/2020

FES PET Submitted by Zionexa on 07/29/2020

PET/CT Submitted by Society of Interventional Radiology on 07/30/2020

EndoPredict Submitted by Myriad Genetics Laboratories, Inc. on 08/01/2020

PET/CT Submitted by MD Anderson Cancer Center on 08/04/2020

Pertuzumab + ado-trastuzumab emtansine Submitted by Genentech Inc. on 08/05/2020

Breast Cancer Index Submitted by Biotheranostics Inc. on 08/05/2020

Breast Cancer Index Submitted by Biotheranostics Inc. on 08/05/2020

L-Dex Submitted by ImpediMed Limited on 08/05/2020

Neratinib Submitted by Puma Biotechnology on 08/05/2020

NGS assay Submitted by Guardant Health on 08/06/2020

NGS assay Submitted by Foundation Medicine Inc. on 08/06/2020

TMB testing Submitted by Foundation Medicine Inc. on 09/15/2020

Neratinib Submitted by Puma Biotechnology on 10/05/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 11/16/2020

Atezolizumab + albumin-bound paclitaxel Submitted by Genentech Inc. on 12/02/2020

riskScore™ Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2020

BBDRisk Dx® MAAA (Multianalyte Assays with Algorithmic Analysis) Submitted by Silbiotech on 07/10/2020

Breast-Specific Gamma Imaging (BSGI) Submitted by Mandell and Blau MD’s PC/Legacy Medical Group-Surgical Oncology on 12/17/2014

Digital Breast Tomosynthesis Submitted by Hologic, Inc. on 12/18/2015

Digital Breast Tomosynthesis Submitted by University of Pennsylvania School of Medicine on 01/14/2016

Breast Cancer Family Histories Submitted by Myriad Genetic Laboratories, Inc. on 02/05/2016

Digital Breast Tomosynthesis Submitted by Hologic, Inc. on 10/28/2018

ESA REMS and ESA APPRISE Oncology Programs Submitted by Amgen, Inc. on 04/14/2017

Pomalidomide Submitted by Bristol-Myers Squibb Company on 05/19/2020

Tinzaparin Submitted by LEO Pharma on 10/20/2014

Apixaban Submitted by Bristol-Myers Squibb Company on 12/21/2018

Apixaban Submitted by Bristol-Myers Squibb Company on 11/06/2019

Apixaban Submitted by Bristol-Myers Squibb Company on 04/06/2020

Andexanet alfa Submitted by Bristol Myers Squibb on 06/25/2020

Acute DVT Submitted by Society of Interventional Oncology on 10/27/2020

Sunitinib Submitted by Pfizer Inc, Pfizer Oncology on 08/20/2014

NovoTTF^TM-100A System Submitted by Musella Foundation For Brain Tumor Research & Information, Inc on 10/01/2014

NovoTTF^TM-100A System Submitted by Novocure Inc. on 10/01/2014

NovoTTF^TM-100A System Submitted by Accelerate Brain Cancer Cure on 11/24/2014

NovoTTF^TM-100A System Submitted by Musella Foundation For Brain Tumor Research & Information, Inc on 11/24/2014

NovoTTF^TM-100A System Submitted by National Brain Tumor Society on 11/25/2014

CNS brain metastatic lesions Submitted by Jiang Aijun and Zheng Xia on 08/23/2015

Tumor treating fields (TTFields) Submitted by Novocure Inc. on 11/06/2015

Radiation therapy recommendations Submitted by The American Society for Radiation Oncology (ASTRO) on 12/02/2015

TTFields update Submitted by Novocure Inc. on 12/15/2015

Radiation therapy recommendations Submitted by The American Society for Radiation Oncology (ASTRO) on 06/13/2016

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/05/2017

Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/27/2017

Osimertinib Submitted by AstraZeneca Pharmaceuticals LP on 04/19/2018

Bevacizumab Submitted by Munson Medical Oncology on 05/02/2018

Glucarpidase Submitted by BTG International Inc. on 09/13/2018

Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018

Osimertinib Submitted by AstraZeneca on 01/17/2019

Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 04/05/2019

Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 05/28/2019

Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 06/10/2019

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/18/2019

Bevacizumab-awwb Submitted by Amgen on 07/19/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Tucatinib Submitted by Seattle Genetics, Inc. on 04/17/2020

Tamoxifen Submitted by Sarcoma Unit Royal Marsden Hospital, United Kingdom on 08/15/2012

Bevacizumab Submitted by Genentech on 02/20/2014

Trabectedin Submitted by Janssen Biotech, Inc. on 10/23/2015

Mutation prediction models (ie MMRpro, PREMM [1,2,6] or MMRpredict) Submitted by Myriad Genetic Laboratories, Inc. on 05/02/2016

Olaratumab in combination with doxorubicin Submitted by Eli-Lilly and Company on 03/22/2017

Genetic counseling/testing for patients without MMR abnormalities Submitted by Myriad Genetic Laboratories, Inc. on 03/29/2017

Pembrolizumab for MSI-H/dMMR tumors for Cervical Cancer Submitted by Merck & Co. on 05/31/2017

Pembrolizumab for MSI-H/dMMR tumors for Uterine Neoplasms Submitted by Merck & Co. on 05/31/2017

Pembrolizumab for MSI-H/dMMR tumors for Vulvar Cancer Submitted by Merck & Co. on 05/31/2017

Trastuzumab Submitted by Genentech, Inc. on 04/26/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 06/12/2018

Radiation Therapy Submitted by American Society for Radiation Oncology on 04/30/2019

PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 05/17/2019

Lenvatinib in combination with pembrolizumab Submitted by Eisai Inc. on 06/28/2019

Bevacizumab-awwwb Submitted by Amgen on 07/19/2019

Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech on 08/15/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Nivolumab Submitted by Bristol-Myers Squibb on 10/17/2019

Nivolumab for Vulvar Cancer Submitted by Bristol-Myers Squibb on 10/17/2019

Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb on 12/04/2019

Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020

Pembrolizumab Submitted by Merck & Co, Inc. on 03/20/2020

Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab dosing for Vulvar Cancer Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020

Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GSK on 05/15/2020

Pembrolizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 06/17/2020

Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020

Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 06/17/2020

Pembrolizumab and TMB testing for Cervical Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020

Pembrolizumab and TMB testing for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020

Pembrolizumab and TMB testing for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 06/30/2020

Avelumab Submitted by EMD Serono, Inc. on 08/11/2020

Dostarlimab-gxly (Uterine Neoplasms) Submitted by GlaxoSmithKline on 04/22/2021

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 06/07/2010

Bosutinib Submitted by Pfizer Oncology on 09/04/2012

Ponatinib Submitted by Ariad Pharmaceuticals on 12/21/2012

Ponatinib Submitted by Ariad Pharmaceuticals on 01/09/2014

Ponatinib Submitted by Ariad Pharmaceuticals on 05/16/2014

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 06/17/2016

Bosutinib Submitted by Pfizer Inc. on 11/01/2017

Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/17/2017

Dasatinib Submitted by Bristol-Myers Squibb Company on 12/10/2017

Bosutinib Submitted by Pfizer Inc. on 12/19/2017

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 01/18/2018

Next-generation sequencing Submitted by Illumina Inc. on 02/27/2018

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 03/22/2018

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 03/22/2018

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 05/02/2019

Ponatinib Submitted by Takeda Oncology on 10/21/2020

Ibrutinib Submitted by Pharmacyclics, LLC on 02/27/2017

Serum free light chain assays Submitted by Aurora Health Care on 04/07/2017

Rituximab/Hyaluronidase Submitted by Genentech, Inc. on 05/20/2017

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Ibrutinib Submitted by Pharmacyclics, LLC on 06/05/2017

Ibrutinib Submitted by Pharmacyclics LLC on 08/02/2017

Obinutuzumab Submitted by Genentech, Inc. on 08/10/2017

Defibrotide sodium Submitted by Jazz Pharmaceuticals on 11/27/2017

Venetoclax Submitted by AbbVie Inc. on 12/13/2017

Ibrutinib Submitted by Pharmacyclics LLC on 12/21/2017

TP53 genetic sequencing Submitted by Illumina Inc. on 04/06/2018

Ibrutinib Submitted by Pharmacyclics LLC on 06/20/2018

Venetoclax Submitted by AbbVie Inc. on 06/21/2018

Moxetumomab pasudotox-tdfk Submitted by AstraZeneca on 09/15/2018

Duvelisib Submitted by Verastem, Inc. on 09/25/2018

Ibrutinib Submitted by Pharmacyclics LLC on 12/20/2018

Acalabrutinib Submitted by AstraZeneca on 12/21/2018

clonoSEQ assay Submitted by Adaptive Biotechnologies Corporation on 05/13/2019

Venetoclax Submitted by AbbVie Inc. on 05/16/2019

Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 06/05/2019

Venetoclax + Rituximab Submitted by AbbVie Inc. on 06/05/2019

Acalabrutinib Submitted by AstraZeneca on 06/26/2019

Ibrutinib Submitted by Pharmacyclics LLC on 06/28/2019

Acalabrutinib Submitted by AstraZeneca on 07/09/2019

Rituximab-abbs Submitted by Teva Pharmaceuticals USA, Inc. on 09/23/2019

Acalabrutinib Submitted by AstraZeneca/Medical Affairs on 11/21/2019

Zanubrutinib Submitted by BeiGene, Ltd. on 12/17/2019

Moxetumomab pasudotox-tdfk Submitted by Innate Pharma, Inc. on 05/08/2020

clonoSEQ Submitted by Adaptive Biotechnologies Corporation on 05/12/2020

Ibrutinib Submitted by Pharmacyclics LLC on 05/15/2020

Zanubrutinib Submitted by BeiGene, Ltd. on 05/15/2020

Acalabrutinib Submitted by AstraZeneca on 05/23/2020

Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 06/02/2020

Zanubrutinib Submitted by BeiGene, Ltd. on 08/03/2020

Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 09/11/2020

Bevacizumab Submitted by Genentech on 06/08/2010

Cetuximab Submitted by Bristol-Myers Squibb on 05/16/2011

Capecitabine (Colon Cancer) Submitted by Genentech on 06/07/2011

Capecitabine (Rectal Cancer) Submitted by Genentech on 06/07/2011

Bevacizumab Submitted by Genentech on 06/05/2012

Ziv-aflibercept Submitted by Sanofi on 08/03/2012

Regorafenib Submitted by Bayer HealthCare on 10/03/2012

Fluoropyrimidine Pre-Screening Submitted by Ken Surprenant on 03/23/2014

Oncotype DX® Colon Cancer Assay Submitted by Genomic Health on 05/16/2014

PET/CT Submitted by Medical Imaging & Technology Alliance on 05/28/2014

PET/CT Submitted by Medical Imaging & Technology Alliance on 05/28/2014

Bevacizumab Submitted by Genentech on 06/02/2014

Mitomycin C Submitted by Personalized Cancer Medicine on 02/23/2015

Fluoropyrimidine Submitted by Ken Surprenant on 04/05/2015

Ramucirumab Submitted by Lilly Oncology on 04/28/2015

Ziv-Aflibercept Submitted by Sanofi on 08/18/2015

Regorafenib Submitted by Bayer HealthCare on 08/19/2015

Trifluridine and Tipiracil Submitted by Taiho Oncology on 09/22/2015

Pembrolizumab Submitted by Merck & Co., Inc. on 02/01/2016

Uridine Triacetate Submitted by Wellstat Therapeutics Corporation on 07/01/2016

Yttrium-90 resin microspheres Submitted by Sirtex Medical Inc. on 07/15/2016

Cytoreductive surgery and intraperitoneal chemotherapy Submitted by Kiran K. Turaga MD MPH, H. Richard Alexander MD PhD, and David Bartlett MD on 07/20/2016

EGFR tumor location Submitted by Amgen, Inc. on 12/19/2016

Panitumumab Submitted by Amgen, Inc. on 01/30/2017

Vemurafenib Submitted by Genentech, Inc. on 02/22/2017

Fluoropyrimidine Submitted by Kenneth E. Surprenant on 04/24/2017

Ziv-aflibercept Submitted by Sanofi Genzyme on 05/15/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 05/22/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2017

Vemurafenib Submitted by Genentech, Inc. on 07/21/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 08/01/2017

Oncotype DX® Colon Recurrence Score® assay Submitted by Genomic Health, Inc. on 08/07/2017

CGP assays Submitted by Foundation Medicine, Inc. on 08/10/2017

Yttrium-90 Submitted by Sirtex Medical Limited on 08/16/2017

RAS molecular testing Submitted by Illumina Inc. on 01/03/2018

RAS molecular testing Submitted by Illumina Inc. on 01/03/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 01/22/2018

Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 01/26/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Trastuzumab + Pertuzumab Submitted by Genentech, Inc. on 05/11/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 07/11/2018

Immunoscore testing Submitted by HalioDx on 07/24/2018

Radiation Therapy Submitted by American Society for Radiation Oncology (ASTRO) on 07/31/2018

Yttrium 90 Submitted by Sirtex Medical Inc on 08/02/2018

Atezolizumab Submitted by Genentech, Inc. on 08/07/2018

Fluoropyrimidines Submitted by Gabriel A. Brooks, MD, MPH & Ken Surprenant on 08/08/2018

Comprehensive Genomic Profiling (CGP) assay Submitted by Foundation Medicine, Inc. on 08/09/2018

Yttrium 90 Submitted by Sirtex Medical Inc on 08/10/2018

Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018

Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 02/26/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 04/19/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 05/03/2019

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/03/2019

Transanal full thickness local excision Submitted by Ascension St. John Hospital on 06/04/2019

Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 07/16/2019

Bevacizumab-awwb Submitted by Amgen on 07/19/2019

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019

Levoleucovorin Submitted by Acrotech Biopharma LLC on 07/25/2019

DPYD genetic testing Submitted by University of Michigan College of Pharmacy on 07/29/2019

MSI Assays Submitted by Promega Corporation on 07/29/2019

Regorafenib + Nivolumab Submitted by Bayer Healthcare Pharmaceuticals on 07/30/2019

yttrium-90 Submitted by Society of Interventional Oncology on 08/08/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Comprehensive genomic profiling (CGP) Submitted by Guardant Health, Inc. on 01/30/2020

Pembrolizumab for Anal Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/01/2020

Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/01/2020

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 06/01/2020

Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 06/10/2020

Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020

Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020

Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020

Immunoscore assay Submitted by HalioDx on 06/25/2020

Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/30/2020

Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/30/2020

Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals LP on 07/09/2020

Post-surgical tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020

Tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020

Post-surgical tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020

Tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020

yttrium-90 Submitted by Society of Interventional Oncology on 07/14/2020

Next-generation sequencing (NGS) Submitted by Guardant Health, Inc. on 07/20/2020

Circulating Tumor DNA (ctDNA) Submitted by Colorectal Cancer Alliance on 08/10/2020

Tumor Mutational Burden (TMB) for Small Bowel Adenocarcinoma Submitted by Foundation Medicine, Inc. on 09/16/2020

Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020

Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020

Average-risk CRC screening Submitted by Exact Sciences Corporation on 10/29/2018

Epi proColon Submitted by Epigenomics AG on 12/05/2019

Epi proColon Submitted by Epigenomics Inc. on 09/28/2020

FIT-DNA-based testing Submitted by Exact Sciences Corporation on 10/13/2020

PHQ-2 and PHQ-9 Questionnaire Submitted by Wake Forest School of Medicine on 12/21/2016

Capecitabine Submitted by Genentech on 08/17/2011

Albumin-bound paclitaxel Submitted by Celgene on 10/02/2013

Nivolumab or nivolumab in combination with ipilimumab Submitted by Bristol-Myers Squibb on 06/04/2016

Uridine triacetate Submitted by Wellstat Therapeutics Corporation on 08/17/2016

High‐Risk Syndromes Submitted by Myriad Genetic Laboratories, Inc. on 08/17/2016

Pembrolizumab for Gastric Cancer Submitted by Merck & Co. on 05/31/2017

Pembrolizumab for Esophageal Cancer Submitted by Merck & Co. on 05/31/2017

Pertuzumab in combination with trastuzumab and chemotherapy Submitted by Genentech, Inc. on 09/15/2017

Pertuzumab in combination with trastuzumab and chemotherapy for HER2 positive tumors for Esophageal and Esophagogastric Cancer Submitted by Genentech, Inc. on 09/15/2017

Nivolumab for Gastric Cancer Submitted by Bristol-Myers Squibb on 09/21/2017

Nivolumab for Esophageal and Esophagogastric Cancer Submitted by Bristol-Myers Squibb on 09/21/2017

Pembrolizumab for PD-L1 tumors for Gastric Cancer Submitted by Merck & Co. on 09/29/2017

Pembrolizumab for PD-L1 tumors for Esophageal and Esophagogastric Cancer Submitted by Merck & Co. on 09/29/2017

Trifluridine/Tipiracil Submitted by Taiho Oncology, Inc. on 07/13/2018

Trastuzumab Submitted by Eli Lilly and Company on 07/17/2018

Principles of Pathologic Review Submitted by Foundation Medicine, Inc. on 09/11/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 01/29/2019

Trastuzumab-dkst Submitted by Mylan N.V. on 06/26/2019

Trastuzumab-anns Submitted by Amgen on 07/19/2019

Scalp cooling system for Esophageal and Gastric Submitted by Paxman Coolers Limited on 07/26/2019

Regorafenib plus nivolumab for Gastric Cancer Submitted by Bayer Healthcare Pharmaceuticals on 07/30/2019

Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd on 08/02/2019

Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech, Inc. on 08/15/2019

Comprehensive genetic profiling Submitted by Foundation Medicine, Inc. on 09/05/2019

Wide area transepithelial sampling for Esophageal Cancer Submitted by CDx Diagnostics, Inc on 09/06/2019

Pembrolizumab Submitted by Oncology Analytics on 09/18/2019

PCR-based microsatellite instability assays for Esophageal and Gastric Cancer Submitted by Promega Corporation on 09/23/2019

Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb on 09/30/2019

Plasma-based comprehensive genomic profiling for Esophageal Cancer Submitted by Guardant Health on 01/30/2020

Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 03/12/2020

Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab for Esophageal and Esophagogastric Cancer Submitted by Merck & Co., Inc on 04/29/2020

Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc on 04/29/2020

Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/04/2020

Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by Daiichi-Sankyo and Astrazeneca Pharmaceuticals on 06/04/2020

Nivolumab for Esophageal squamous cell carcinoma Submitted by Bristol Myers Squibb on 06/11/2020

Pembrolizumab for TMB-H for Esophageal Cancer Submitted by Merck & Co., Inc. on 06/17/2020

Pembrolizumab for TMB for Gastric Cancer Submitted by Merck & Co., Inc. on 06/17/2020

Tumor mutational burden (TMB) testing for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020

Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020

Comprehensive genomic profiling for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020

Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020

Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/26/2020

Pembrolizumab with chemotherapy for Esophageal Cancer Submitted by Merck & Co., Inc. on 09/21/2020

Nivolumab for Esophageal Cancer Submitted by Bristol Myers Squibb, Inc. on 09/23/2020

Nivolumab for Gastric Cancer Submitted by Bristol Myers Squibb, Inc. on 09/23/2020

Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 11/04/2020

Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by Daiichi-Sankyo and Astrazeneca Pharmaceuticals on 01/21/2021

Familial Risk Management Submitted by Myriad on 10/19/2015

Multi-Gene Panel Submitted by Myriad on 10/19/2015

Multigene Panel Testing Submitted by Myriad Genetic Laboratories, Inc. on 05/14/2016

Personal History of Pancreatic Cancer Submitted by Myriad Genetic Laboratories, Inc. on 05/14/2016

PALB2 Submitted by Myriad Genetic Laboratories, Inc. on 04/11/2017

BRCA testing Submitted by Myriad Genetic Laboratories, Inc. on 04/17/2017

Multigene Panel Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/17/2017

Genetic risk evaluation Submitted by Baltimore Suburban Health on 08/03/2017

Next-generation sequencing Submitted by Illumina Inc. on 10/18/2017

Further Risk Evaluation Submitted by Myriad Genetic Laboratories, Inc. on 03/09/2018

HBOC‐related cancer Submitted by Myriad Genetic Laboratories, Inc. on 03/09/2018

RAD51D gene variations Submitted by Hines & Associates, Inc on 02/28/2019

Genetic Testing Submitted by Myriad Genetics, Inc. on 04/01/2019

Prostate Cancer Testing Criteria Submitted by Myriad Genetics, Inc. on 04/02/2019

PALB2 testing criteria Submitted by Myriad Genetics, Inc. on 04/03/2019

Personal history of ovarian carcinoma Submitted by Myriad Genetics, Inc. on 04/03/2019

Genetic Testing Submitted by Oneinforty on 04/24/2019

Genetic Testing Submitted by University of Minnesota Medical Center on 05/31/2019

BARD1- and RAD51D-associated breast cancer risk Submitted by Ambry Genetics on 10/03/2019

Multi-gene testing Submitted by Ambry Genetics on 10/03/2019

Olaparib Submitted by AstraZeneca on 10/07/2019

Breast Cancer diagnosis less than 66 years old Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020

High Penetrance Genes Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020

Prostate Cancer Testing Criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/01/2020

Lynch Syndrome Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019

Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019

CRC Modifications Submitted by Myriad Genetics Laboratories, Inc. on 11/05/2020

Multi-syndrome gene panel Submitted by Myriad on 10/08/2015

Cologuard Submitted by Exact Sciences Inc. on 05/27/2016

Genetic risk assessment Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016

LS-specific testing Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016

Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016

MSI‐H histology Submitted by Myriad Genetic Laboratories, Inc. on 10/01/2017

Epi proColon Submitted by Epigenomics Inc. on 09/25/2018

Fluoropyrimidine Pre-Screening Submitted by Ken Surprenant on 04/06/2014

Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc on 06/10/2015

Nivolumab Submitted by Bristol Myers Squibb Company on 04/19/2016

Nivolumab Submitted by Bristol Myers Squibb Company on 06/06/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 06/15/2016

Principles of Nutrition Submitted by Oncology Nutrition Dietetic Practice Group, Academy of Nutrition and Dietetics on 07/06/2016

Technetium Tc 99m tilmanocept Submitted by Navidea Biopharmaceuticals on 07/18/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 08/05/2016

Hybrid capture based NGS Submitted by Foundation Medicine, Inc. on 08/22/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 09/19/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 10/03/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 04/06/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 04/13/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 04/16/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2018

Larotrectinib Submitted by Bayer HealthCare Pharmaceuticals on 10/15/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 10/22/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 12/07/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 06/26/2019

Radiation Therapy Submitted by ASTRO on 08/13/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 11/07/2019

Trastuzumab/pertuzumab Submitted by Genentech on 02/18/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Radiation Therapy Submitted by ASTRO on 05/28/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

NCCN Evidence Blocks Submitted by Merck & Co., Inc. on 06/18/2020

TMB Submitted by Foundation Medicine on 06/22/2020

TMB Submitted by Foundation Medicine on 09/15/2020

Abatacept Submitted by Bristol-Myers Squibb Company on 08/01/2019

Defibrotide sodium Submitted by Jazz Pharmaceuticals on 08/02/2019

Defibrotide sodium Submitted by Jazz Pharmaceuticals on 10/22/2020

Filgrastim-sndz Submitted by Sandoz Inc. on 02/04/2015

Pegfilrastim delivery kit/on-body injector Submitted by Amgen, Inc. on 05/13/2015

Regimens with a high/intermediate risk for febrile neutropenia Submitted by Hospital Universitario de Getafe on 10/20/2015

Plerixafor dosing and references Submitted by Sanofi U.S. on 12/14/2015

Febrile neutropenia risk of CHOP/R-CHOP Submitted by Amgen Inc. on 05/22/2017

MGF in the palliative setting Submitted by William Stephenson, MD on 07/21/2017

Ferumoxytol Submitted by AMAG Pharmaceuticals on 04/10/2018

Epoetin alfa-epbx Submitted by Pfizer Inc. on 05/31/2018

Filgrastim-aafi Submitted by Pfizer on 08/09/2018

Pegfilgrastim-jmdb Submitted by Mylan on 10/24/2018

5-flurorouracil, oxaliplatin, leucovorin Submitted by Oncology Analytics, Inc. on 02/05/2019

Pegfilgrastim-cbqv Submitted by Coherus BioSciences on 02/11/2019

Filgrastim-sndz Submitted by Sandoz Inc. on 09/09/2019

Eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc on 08/31/2020

Granulocyte Colony Stimulating Factors (G-CSF) Submitted by The University of Arizona Cancer Center on 09/17/2020

Pegfilgrastim Submitted by Coherus Biosciences on 09/17/2020

Trilaciclib Submitted by G1 Therapeutics on 09/18/2020

Ferric Derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 09/21/2020

Trilaciclib Submitted by G1 Therapeutics on 02/12/2021

Regorafenib Submitted by Bayer HealthCare on 06/30/2016

Nivolumab Submitted by Bristol-Myers Squibb Company on 09/26/2016

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 06/06/2018

Ramucirumab Submitted by Eli Lilly and Company on 06/22/2018

Cabozantinib Submitted by Exelixis, Inc. on 07/13/2018

Lenvatinib Submitted by Eisai Inc. on 08/16/2018

Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018

Lenvatinib Submitted by Eisai Inc. on 09/10/2018

Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 10/30/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 11/12/2018

Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 12/19/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 01/18/2019

Ramucirumab Submitted by Eli Lilly and Company on 05/16/2019

Larotrectinib Submitted by Bayer HealthCare on 05/28/2019

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/11/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 06/14/2019

Entrectinib Submitted by Bayer HealthCare on 08/15/2019

Molecular Testing Submitted by Bayer HealthCare on 08/23/2019

Locoregional therapy Submitted by Society of Interventional Oncology on 08/26/2019

Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 09/24/2019

Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 09/27/2019

Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 10/01/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 10/02/2019

Lenvatinib Submitted by Eisai Inc. on 11/12/2019

Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 11/23/2019

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 03/11/2020

Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/13/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pemigatinib Submitted by Incyte Corporation on 04/17/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Molecular testing Submitted by Foundation Medicine, Inc. on 05/14/2020

Lenvatinib Submitted by Eisai Inc. on 05/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020

Lenvatinib Submitted by Eisai Inc. on 08/12/2020

Radioembolization Submitted by Society of Interventional Oncology on 10/01/2020

Ipilimumab Submitted by Bristol Myers Squibb on 10/02/2020

Pralsetinib Submitted by Blueprint Medicines Corporation on 10/02/2020

Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 10/08/2020

Brentuximab Submitted by Seattle Genetics on 08/22/2011

Brentuximab vedotin Submitted by Seattle Genetics on 09/05/2014

Brentuximab vedotin Submitted by Seattle Genetics on 09/05/2014

Panobinostat Submitted by Novartis Pharmaceuticals Organization on 02/24/2015

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/25/2015

Nivolumab Submitted by Bristol-Myers Squibb on 05/18/2016

Nivolumab Submitted by Bristol-Myers Squibb on 07/21/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 03/22/2017

Vitamin D-25OH and bone mineral density testing Submitted by Aurora Health Care on 04/07/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 04/25/2017

Brentuximab vedotin Submitted by Seattle Genetics on 05/05/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 08/14/2017

Brentuximab vedotin + AVD Submitted by Seattle Genetics Inc. on 12/10/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/20/2018

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 04/15/2019

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/26/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020

Cabozantinib Submitted by Exelixis, Inc. on 06/06/2016

Cabozantinib Submitted by Exelixis, Inc. on 11/14/2016

Sunitinib Submitted by Pfizer Oncology on 01/12/2017

Radiation Therapy Submitted by American Society for Radiation Oncology on 05/24/2017

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Sunitinib Submitted by Pfizer Oncology on 06/19/2017

Atezolizumab Submitted by Genentech, Inc. on 02/14/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 02/16/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 04/16/2018

Pazopanib Submitted by Novartis Pharmaceuticals Corporation on 05/29/2018

Atezolizumab Submitted by Genentech, Inc. on 06/25/2018

Cabozantinib Submitted by Exelixis, Inc. on 06/26/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 07/02/2018

Avelumab + Axitinib Submitted by EMD Serono, Inc. on 02/20/2019

T1a renal masses Submitted by Society of Interventional Oncology on 03/15/2019

Cabozantinib Submitted by Exelixis, Inc. on 03/21/2019

Atezolizumab Submitted by Genentech, Inc. on 05/13/2019

Bevacizumab Submitted by Amgen on 07/19/2019

Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020

Thermal Ablation Submitted by Society of Interventional Oncology on 03/02/2020

Lenvatinib Submitted by Eisai Inc. on 03/12/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Nivolumab + Cabozantinib Submitted by Bristol Myers Squibb on 01/25/2021

Nivolumab + Cabozantinib Submitted by Exelixis, Inc. on 01/25/2021

Lenvatinib + pembrolizumab Submitted by Eisai Inc. on 02/13/2021

Nivolumab + Cabozantinib Submitted by Bristol Myers Squibb on 03/04/2021

Cabozantinib + Nivolumab Submitted by Exelixis, Inc. on 03/05/2021

Tivozanib Submitted by AVEO Oncology on 03/12/2021

Denosumab Submitted by Amgen on 07/18/2011

Axitinib Submitted by Pfizer Oncology on 01/31/2012

Everolimus Submitted by Novartis Pharmaceutical Corporation on 12/13/2012

Axitinib Submitted by Pfizer on 02/24/2014

Lenvatinib Submitted by Eisai Inc. on 09/08/2015

Cabozantinib Submitted by Exelixis, Inc. on 09/26/2015

Nivolumab Submitted by Bristol-Myers Squibb on 09/28/2015

Nivolumab Submitted by Bristol-Myers Squibb on 11/23/2015

Lenvatinib Submitted by Eisai, Inc. on 05/26/2016

Tomosynthesis Submitted by General Electric Healthcare on 03/07/2014

23-gene bronchial genomic classifier Submitted by Veracyte, Inc. on 03/12/2018

Cetirizine hydrochloride Submitted by TerSera Therapeutics on 11/07/2019

Guardant360 Submitted by Guardant Health, Inc. on 06/15/2020

Ipilimumab Submitted by Bristol-Myers Squibb on 03/25/2011

Vemurafenib Submitted by Genentech on 08/22/2011

Albumin-bound paclitaxel Submitted by Celgene on 12/21/2012

Pembrolizumab Submitted by Merck & Co, Inc on 09/08/2014

Pembrolizumab Submitted by Merck & Co, Inc on 09/08/2014

Nivolumab Submitted by Bristol-Myers Squibb Company on 12/22/2014

Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/15/2015

Pembrolizumab Submitted by Merck & Co., Inc. on 05/05/2015

Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 05/20/2015

Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/01/2015

Talimogene laherparepvec Submitted by Amgen Inc. on 10/28/2015

Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/29/2015

Cobimetinib/vemurafenib Submitted by Genentech, Inc. on 11/10/2015

Cobimetinib Submitted by Genentech, Inc. on 11/24/2015

Nivolumab Submitted by Bristol-Myers Squibb Company on 11/30/2015

Pembrolizumab Submitted by Merck & Co., Inc on 03/09/2016

Pembrolizumab Submitted by Merck & Co., Inc on 06/19/2016

Decision Dx-Melanoma test Submitted by Castle Biosciences, Inc. on 06/24/2016

Counseling and genetic testing Submitted by Oregon Health and Science University on 06/27/2016

Genetic risk assessment/testing Submitted by Myriad Genetic Laboratories, Inc. on 06/29/2016

Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/09/2016

Nivolumab/ipilimumab Submitted by Bristol-Myers Squibb Company on 04/04/2017

Pembrolizumab for MSI-H/dMMR tumors Submitted by Merck & Co. on 05/31/2017

DecisionDx-Melanoma test Submitted by Castle Biosciences Incorporated on 06/01/2017

Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/05/2017

myPath Melanoma 23-gene diagnostic expression signature Submitted by Myriad Genetic Laboratories, Inc. on 06/06/2017

CDx assay Submitted by Foundation Medicine, Inc. on 06/07/2017

Talimogene Laherparepvec in combination with ipilimumab Submitted by Amgen Inc. on 06/29/2017

Nivolumab Submitted by Bristol-Myers Squibb on 09/11/2017

Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/11/2017

Vemurafenib Submitted by Genentech, Inc. on 09/15/2017

Dabrafenib/trametinib Submitted by Novartis on 09/27/2017

Talimogene laherparepvec Submitted by Amgen, Inc. on 10/16/2017

Nivolumab Submitted by Bristol-Myers Squibb on 12/21/2017

Talimogene laherparepvec/ipilimumab Submitted by Amgen on 02/28/2018

Talimogene laherparepvec/pembrolizumab Submitted by Amgen on 02/28/2018

Nivolumab Submitted by Bristol-Myers Squibb on 03/06/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 04/15/2018

Next-generation based testing Submitted by Illumina Inc. on 05/18/2018

Dabrafenib/Trametinib Submitted by Novartis on 05/30/2018

Adhesive patch based non-invasive skin sampling tool Submitted by DermTech on 05/31/2018

Encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) Submitted by Array BioPharma Inc. on 06/20/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 11/29/2018

Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018

Pigmented Lesion Assay (PLA) Submitted by DermTech on 06/27/2019

DecisionDx-Melanoma Test Submitted by Castle Biosciences, Incorporated on 06/28/2019

Principles of Molecular Testing revisions Submitted by Myriad Genetic Laboratories, Inc on 06/28/2019

Genetic testing for inherited melanoma risk Submitted by Myriad Genetic Laboratories, Inc on 06/29/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 01/13/2020

Pembrolizumab dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020

Pembrolizumab dosing Submitted by Merck & Co., Inc. on 04/29/2020

Footnote and gene mutation listings Submitted by Myriad Genetic Laboratories, Inc. on 06/09/2020

Pembrolizumab weight-based dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020

GEP using DecisionDx-UM for Uveal Melanoma Submitted by Castle Biosciences on 06/15/2020

Pembrolizumab and low-dose ipilimumab for second- or subsequent line therapy Submitted by Merck & Co., Inc. on 06/16/2020

Pigmented lesion assay (PLA) Submitted by DermTech, Inc. on 06/16/2020

DecisionDx-Melanoma test (31-GEP) Submitted by Castle Biosciences on 06/17/2020

PLA Submitted by Dermatologic Surgery Center of Washington, LLC on 06/21/2020

Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 06/22/2020

Gene expression profiling (GEP) Submitted by Myriad Genetic Laboratories, Inc. on 06/22/2020

PLA Submitted by SUNY Downstate on 06/22/2020

PLA Submitted by University of Pittsburgh School of Medicine Department of Dermatology on 06/23/2020

PLA Submitted by Northwestern University Feinberg School of Medicine, Department of Dermatology on 06/23/2020

Pembrolizumab and low-dose ipilimumab for first-line Submitted by Merck & Co., Inc. on 07/21/2020

Atezolizumab in combination with cobimetinib and vemurafenib for Cutaneous Melanoma Submitted by Genentech, Inc. on 07/30/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 08/12/2020

Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 09/15/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 01/06/2021

Zoledronic Acid Submitted by Novarits on 03/09/2011

Bortezomib Submitted by Millennium on 03/25/2011

Bortezomib Submitted by Millennium on 03/25/2011

Vorinostat Submitted by Merck on 02/24/2012

Bortezomib Submitted by Millennium on 04/10/2012

Bortezomib Submitted by Millennium on 04/10/2012

Lenalidomide Submitted by Celgene on 05/17/2012

Carfilzomib Submitted by Onyx on 07/30/2012

Carfilzomib Submitted by Onyx on 01/17/2013

Pomalidomide Submitted by Celgene on 02/11/2013

Bortezomib Submitted by Millennium on 03/28/2013

Bortezomib Submitted by Millennium on 03/28/2013

Bortezomib Submitted by Millennium on 03/28/2013

Carfilzomib Submitted by Onyx on 04/19/2013

Lenalidomide Submitted by Celgene on 07/31/2013

Ibrutinib Submitted by Janssen Biotech on 11/13/2013

Pomalidomide Submitted by Celgene on 10/09/2014

Panobinostat Submitted by Novartis on 08/12/2015

Daratumumab Submitted by Janssen Biotech, Inc. on 11/23/2015

Elotuzumab Submitted by Bristol-Myers Squibb Company on 11/30/2015

Ixazomib Submitted by Takeda on 12/01/2015

Ixazomib Submitted by Takeda on 12/01/2015

Ixazomib Submitted by Takeda on 12/11/2015

Carfilzomib Submitted by Amgen Inc. on 02/11/2016

Carfilzomib Submitted by Amgen Inc. on 02/11/2016

Bendamustine Hydrochloride Submitted by Teva Pharmaceuticals, Inc. on 03/23/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Lenalidomide Submitted by Celgene Corporation on 04/08/2016

Lenalidomide Submitted by Celgene Corporation on 04/08/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Pomalidomide Submitted by Celgene Corporation on 04/08/2016

Panobinostat Submitted by Novartis Pharmaceuticals Corporation on 04/11/2016

Carfilzomib Submitted by The University of Chicago, Department of Medicine on 04/11/2016

Elotuzumab Submitted by Bristol-Myers Squibb Company on 04/21/2016

MyPRS Submitted by Signal Genetics, Inc. on 05/02/2016

MyPRS Submitted by Signal Genetics, Inc. on 05/02/2016

MyPRS Submitted by Signal Genetics, Inc. on 05/02/2016

Daratumumab Submitted by Janssen Biotech, Inc. on 06/07/2016

Lenalidomide Submitted by Celgene Corporation on 06/20/2016

Pomalidomide Submitted by Celgene Corporation on 06/29/2016

Carfilzomib Submitted by Amgen Inc. on 07/27/2016

Carfilzomib Submitted by Amgen Inc. on 07/27/2016

Lenalidomide Submitted by Celgene Corporation on 08/25/2016

Carfilzomib Submitted by Amgen Inc. on 10/07/2016

Lenalidomide Submitted by Celgene Corporation on 10/20/2016

Daratumumab Submitted by Janssen Biotech, Inc. on 10/21/2016

Carfilzomib Submitted by Amgen Inc. on 01/11/2017

Carfilzomib in combination with lenalidomide and dexamethasone Submitted by Amgen Inc. on 01/26/2017

Denosumab Submitted by Amgen Inc. on 03/23/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/02/2017

Pomalidomide Submitted by Celgene Corporation on 07/26/2017

Ibrutinib Submitted by Pharmacyclics, LLC on 08/02/2017

Pomalidomide + Dexamethasone Submitted by Celgene Corporation on 03/30/2018

Lenalidomide Submitted by Celgene Corporation on 04/12/2018

MMprofiler Submitted by SkylineDx, B.V. on 04/18/2018

Ixazomib Submitted by Takeda Oncology on 04/23/2018

Ixazomib ICd Submitted by Takeda Oncology on 04/23/2018

Ixazomib Maintenance Submitted by Takeda Oncology on 04/23/2018

Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2018

Minimal Residual Disease (MRD) analysis Submitted by Adaptive Biotechnologies on 05/10/2018

Daratumumab + Carfilzomib + Dexamethasone Submitted by Janssen Biotech, Inc. on 06/07/2018

Acalabrutinib Submitted by AstraZeneca on 06/11/2018

Ibrutinib Submitted by Pharmacyclics LLC on 06/20/2018

Ixazomib Submitted by Takeda Oncology on 12/02/2018

Daratumumab Submitted by Janssen Biotech, Inc. on 12/06/2018

Ibrutinib Submitted by Pharmacyclics LLC on 12/20/2018

Daratumumab Submitted by Janssen Biotech, Inc. on 02/12/2019

Lenalidomide Submitted by Celgene Corporation on 03/15/2019

Ixazomib Submitted by Takeda Oncology on 03/21/2019

clonoSEQ® assay Submitted by Adaptive Biotechnologies Corporation on 04/26/2019

SKY92 high risk gene expression signature Submitted by SkylineDx on 04/30/2019

SKY92 high risk gene expression signature Submitted by SkylineDx on 04/30/2019

Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2019

Pomalidomide Submitted by Celgene Corporation on 05/14/2019

Daratumumab Submitted by Janssen Biotech, Inc. on 06/07/2019

Selinexor Submitted by Karyopharm Therapeutics on 07/22/2019

Daratumumab Submitted by Janssen Scientific Affairs, LLC on 09/27/2019

Isatuximab Submitted by Sanofi Genzyme on 12/09/2019

Daratumumab Submitted by Janssen Scientific Affairs, LLC on 12/20/2019

Lenalidomide Submitted by Bristol-Myers Squibb Company on 01/16/2020

Isatuximab Submitted by Sanofi Genzyme on 03/02/2020

Dexamethasone Submitted by Acrotech Biopharma, LLC on 03/18/2020

clonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 03/27/2020

Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020

Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020

Ixazomib Submitted by Takeda Oncology on 03/27/2020

Daratumumab Submitted by Janssen Scientific Affairs, LLC on 05/12/2020

Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 06/16/2020

Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 08/05/2020

Carfilzomib Submitted by Amgen Inc. on 08/21/2020

Selinexor Submitted by Karyopharm Therapeutics on 11/12/2020

Ibrutinib Submitted by Pharmacyclics LLC on 12/07/2020

Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 02/01/2021

Melphalan flufenamide Submitted by Oncopeptides, Inc. on 03/01/2021

Idecabtagene Vicleucel Submitted by Bristol Myers Squibb on 03/26/2021

Isatuximab Submitted by Sanofi Genzyme on 03/31/2021

Lenalidomide Submitted by Celgene on 12/22/2014

Lenalidomide Submitted by Celgene on 07/11/2016

Next-generation sequencing Submitted by Illumina Inc. on 11/30/2017

Patient evaluation Submitted by Foundation Medicine, Inc. on 03/26/2018

Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 01/09/2020

Luspatercept-aamt Submitted by Bristol Myers Squibb on 04/10/2020

Decitabine and Cedazuridine Submitted by Taiho Oncology, Inc. on 07/10/2020

Ruxolitinib in patients with intermediate or high‐risk myelofibrosis (MF) Submitted by Incyte Corporation on 07/08/2016

Ruxolitinib in patients with polycythemia vera (PV) Submitted by Incyte Corporation on 07/08/2016

Fedratinib Submitted by Celgene Corporation on 06/27/2019

Fedratinib Submitted by Celgene Corporation on 08/16/2019

Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 07/16/2020

Sunitinib Submitted by Pfizer Oncology on 08/18/2009

Everolimus Submitted by Novartis Pharmaceuticals Corporation on 09/08/2010

Sunitinib Submitted by Pfizer Oncology on 02/25/2011

Lanreotide Submitted by Ipsen Biopharmaceuticals, Inc. on 11/14/2012

Lanreotide Submitted by Ipsen Biopharmaceuticals, Inc. on 06/23/2014

Everolimus Submitted by Novartis Oncology on 10/20/2015

Everolimus Submitted by Novartis Oncology on 03/18/2016

Gallium-68 Dotatate PET/CT Submitted by Medical Imaging and Technology Alliance on 06/15/2016

Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 03/09/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Everolimus + Octreotide (LAR) Submitted by Novartis Pharmaceutical Corporation on 07/07/2017

Lutetium Lu 177 dotatate Submitted by Advanced Accelerator Applications, a Novartis Company on 01/30/2018

HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals, Inc. on 07/10/2018

HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/07/2018

HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/11/2018

Avelumab Submitted by EMD Serono, Inc. on 03/05/2019

Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 05/06/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Copper Cu 64 dotatate Submitted by Curium on 10/07/2019

Liver-Directed Therapy Submitted by Society of Interventional Oncology on 10/15/2019

Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

SSR PET tracer options Submitted by Curium on 09/03/2020

Pralsetinib Submitted by Blueprint Medicines Corporation on 09/10/2020

TMB and pembrolizumab Submitted by Foundation Medicine, Inc. on 09/18/2020

Liver Directed Therapy Submitted by Society of Interventional Oncology on 10/08/2020

Principles of Hormone Control Submitted by TerSera Therapeutics on 10/27/2020

Fludarabine Submitted by sanofi-aventis on 04/05/2010

Alemtuzumab Submitted by Genzyme on 05/10/2010

Ibritumomab Submitted by Spectrum Pharmaceuticals, Inc. on 05/12/2010

Bortezomib Submitted by Millennium on 05/25/2010

Rasburicase Submitted by sanofi-aventis on 05/25/2010

Pralatrexate Submitted by Allos Therapeutics on 06/02/2010

Rituximab Submitted by Genentech on 06/08/2010

Rituximab Submitted by Genentech on 01/11/2011

Bortezomib Submitted by Millennium on 04/08/2011

Rituximab Submitted by Genentech on 06/21/2011

Rituximab Submitted by Genentech on 06/22/2011

Rituximab Submitted by Genentech on 06/22/2011

Rituximab Submitted by Genentech on 06/22/2011

Brentuximab Vedotin Submitted by Seattle Genetics on 08/19/2011

Rituximab Submitted by Genentech on 12/22/2011

Rituximab Submitted by Genentech on 02/29/2012

Glucarpidase Submitted by BTG International on 04/26/2012

Lenalidomide Submitted by Celgene on 06/05/2012

Rituximab Submitted by Genentech on 06/12/2012

Rituximab Submitted by Genentech on 05/07/2013

Brentuximab vedotin Submitted by Seattle Genetics on 06/20/2013

Lenalidomide Submitted by Celgene on 06/27/2013

Lenalidomide Submitted by Celgene on 06/27/2013

Obinutuzumab Submitted by Genentech on 11/01/2013

Ibrutinib Submitted by Janssen Biotech on 11/13/2013

Ibrutinib Submitted by Janssen Biotech on 11/13/2013

Ibrutinib Submitted by Janssen Biotech on 11/13/2013

Ibrutinib Submitted by Janssen Biotech on 11/13/2013

Panobinostat Submitted by Novartis on 02/24/2014

Rituximab Submitted by Genentech on 04/16/2014

Brentuximab vedotin (DLBCL) Submitted by Seattle Genetics on 05/28/2014

Brentuximab vedotin (CTCL) Submitted by Seattle Genetics on 05/28/2014

Bortezomib Submitted by Millennium on 06/02/2014

Obinutuzumab Submitted by Genentech on 06/02/2014

Ibritumomab tiuxetan Submitted by Spectrum Pharmaceuticals on 06/02/2014

Lenalidomide Submitted by Celgene on 06/02/2014

Lenalidomide Submitted by Celgene on 06/03/2014

Ibrutinib (CLL) Submitted by Pharmacyclics on 06/11/2014

Ibrutinib (CLL- elderly) Submitted by Pharmacyclics on 06/11/2014

Idelalisib Submitted by Gilead Sciences on 07/23/2014

Ibrutinib Submitted by Pharmacyclics, Inc. on 07/28/2014

Idelalisib Submitted by Gilead Sciences on 07/30/2014

Ofatumumab Submitted by GlaxoSmithKline on 09/10/2014

Ibrutinib Submitted by Pharmacyclics on 01/29/2015

Obinutuzumab Submitted by Genentech on 06/03/2015

Ibrutinib Submitted by Pharmacyclics on 06/05/2015

Ibrutinib Submitted by Pharmacyclics on 12/07/2015

Ibrutinib Submitted by Pharmacyclics on 12/07/2015

Obinutuzumab Submitted by Genentech on 12/09/2015

Obinutuzumab Submitted by Genentech on 12/09/2015

Obinutuzumab Submitted by Genentech, Inc. on 02/26/2016

Venetoclax Submitted by AbbVie Inc. on 04/12/2016

Ibrutinib Submitted by Pharmacyclics on 05/09/2016

Rasburicase Submitted by Sanofi U.S. on 05/26/2016

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 05/26/2016

Ofatumumab Submitted by Novartis Pharmaceuticals Corporation on 06/03/2016

Obinituzumab Submitted by Genentech, Inc. on 12/05/2016

Ibrutinib + Rituximab Submitted by Pharmacyclics on 12/07/2016

Ibrutinib Submitted by Pharmacyclics on 01/19/2017

Vismodegib Submitted by Genentech on 01/31/2012

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 06/15/2018

Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/28/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 09/29/2019

Pembrolizumab for Basal Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab for Merkel Cell Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 03/26/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/25/2020

Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 06/25/2020

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 07/08/2020

Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/14/2020

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/10/2021

Erlotinib Submitted by Genentech on 06/18/2010

Erlotinib-Bevacizumab Submitted by Genentech on 06/18/2010

Erlotinib Submitted by Genentech on 06/09/2011

Erlotinib Submitted by Genentech on 02/21/2012

Albumin-bound Paclitaxel with Carboplatin Submitted by Celgene on 06/25/2012

Erlotinib Submitted by Genentech on 07/06/2012

Bevacizumab Submitted by Oncology Analytics on 12/31/2012

Afatinib Submitted by Boehringer Ingelheim on 04/24/2013

Bevacizumab Submitted by Genentech on 04/16/2014

Ceritinib Submitted by Novartis on 05/01/2014

FDG PET/CT Submitted by Medical Imaging & Technology Alliance on 06/01/2014

Bevacizumab, Erlotinib Submitted by Genentech on 06/09/2014

Erlotinib Submitted by Genentech on 06/13/2014

VeriStrat® Submitted by Biodesix on 06/18/2014

RNA Assay Submitted by Myriad on 06/25/2014

Oligometastases, Oligorecurrence, and Oligoprogression Submitted by Independent Lung Cancer Patient Advocates on 06/25/2014

Ceritinib Submitted by Novartis on 06/27/2014

Bevacizumab, Erlotinib Submitted by Genentech on 08/28/2014

Vemurafenib, Dabrafenib, Cabozantinib Submitted by Oncology Analytics on 10/06/2014

Ramucirumab Submitted by Lilly Oncology on 12/22/2014

Vemurafenib, Dabrafenib, Crizotinib Submitted by Oncology Analytics on 02/18/2015

Bevacizumab Submitted by Genentech on 03/10/2015

Afatinib with Cetuximab Submitted by Boehringer Ingelheim on 03/23/2015

Pembrolizumab Submitted by Merck on 04/27/2015

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2015

Bevacizumab Submitted by Genentech on 06/08/2015

Afatinib Submitted by Boehringer Ingelheim on 06/10/2015

Cabozantinib Submitted by Exelixis on 06/10/2015

Molecular Testing Submitted by Myriad on 07/06/2015

Afatinib Submitted by Boehringer Ingelheim on 07/07/2015

Validated Comprehensive Genomic Profiling (VCGP) Assays Submitted by Foundation Medicine on 07/10/2015

Gefitinib Submitted by AstraZeneca on 07/27/2015

Pembrolizumab Submitted by Merck on 10/02/2015

Nivolumab Submitted by Bristol-Myers Squibb on 10/09/2015

Necitumumab Submitted by Eli Lilly and Company on 11/25/2015

Ramucirumab Submitted by Eli Lilly and Company on 11/30/2015

Alectinib Submitted by Genentech on 12/11/2015

Pembrolizumab Submitted by Merck on 12/20/2015

Bevacizumab Submitted by Genentech on 01/21/2016

Necitumumab Submitted by Eli Lilly and Company on 03/25/2016

Osimertinib Submitted by AstraZeneca on 05/13/2016

Nivolumab, Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2016

Alectinib Submitted by Genentech, Inc. on 06/06/2016

Molecular Prognostic Score Submitted by Myriad Genetic Laboratories, Inc. on 06/08/2016

Atezolizumab Submitted by Genentech, Inc. on 06/09/2016

Tyrosine Kinase Inhibitors Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 06/15/2016

Test Results Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 06/16/2016

Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 06/17/2016

Osimertinib Submitted by AstraZeneca on 06/17/2016

Erlotinib Submitted by Genentech, Inc. on 06/20/2016

Necitumumab Submitted by Upstage Lung Cancer on 06/20/2016

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/28/2016

Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 08/29/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 10/11/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 10/12/2016

Atezolizumab Submitted by Genentech, Inc. on 10/18/2016

Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 12/05/2016

Atezolizumab Submitted by Genentech, Inc. on 12/12/2016

Osimertinib Submitted by AstraZeneca on 12/14/2016

Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 03/08/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 04/25/2017

Durvalumab Submitted by AstraZeneca on 05/02/2017

Brigatinib Submitted by Takeda Oncology on 05/09/2017

Molecular profiling Submitted by Foundation Medicine, Inc. on 05/26/2017

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 06/01/2017

Alectinib Submitted by Genentech, Inc. on 06/06/2017

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 06/08/2017

Osimertinib Submitted by AstraZeneca on 09/09/2017

Durvalumab Submitted by AstraZeneca on 09/09/2017

Alectinib Submitted by Genentech, Inc. on 11/06/2017

Osimertinib Submitted by AstraZeneca on 11/18/2017

Ramucirumab Submitted by Eli Lilly and Company on 11/20/2017

Guardant360 Submitted by Guardant Health, Inc. on 12/06/2017

Atezolizumab Submitted by Genentech, Inc. on 12/07/2017

Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 01/23/2018

Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 03/06/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 03/08/2018

Next-generation sequencing Submitted by Illumina Inc. on 04/11/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 04/16/2018

Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2018

Osimertinib Submitted by AstraZeneca on 04/18/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 05/02/2018

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/04/2018

Gefitinib Submitted by AstraZeneca on 05/14/2018

Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 05/25/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 06/03/2018

Durvalumab Submitted by AstraZeneca on 06/03/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2018

Atezolizumab and Alectinib Submitted by Genentech, Inc. on 06/04/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2018

Osimertinib Submitted by AstraZeneca on 06/06/2018

Avelumab Submitted by EMD Serono, Inc. on 06/11/2018

Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 06/15/2018

Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 07/24/2018

Guardant360 Submitted by Guardant Health, Inc. on 09/23/2018

Guardant360 Submitted by Guardant Health, Inc., on 09/23/2018

Atezolizumab Submitted by Genentech, Inc. on 09/24/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 09/27/2018

Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018

Dacomitinib Submitted by Pfizer Inc on 10/01/2018

Brigatinib Submitted by Takeda Oncology on 10/02/2018

Brigatinib Submitted by Takeda Oncology on 10/02/2018

Afatinib Addendum Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 10/11/2018

Atezolizumab Submitted by Genentech, Inc. on 10/23/2018

Durvalumab Submitted by AstraZeneca Pharmaceuticals LP/Medical Affairs on 10/25/2018

Nivolumab Submitted by Bristol-Myers Squibb on 10/26/2018

Lorlatinib Submitted by Pfizer Inc. on 11/02/2018

Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018

Osimertinib Submitted by AstraZeneca on 01/17/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 02/13/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 04/12/2019

Durvalumab Submitted by AstraZeneca on 06/03/2019

Brigatinib Submitted by Takeda Oncology on 06/06/2019

Brigatinib Post Crizotinib Submitted by Takeda Oncology on 06/10/2019

Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 06/21/2019

Bevacizumab-awwb Submitted by Amgen on 07/19/2019

Liquid Biopsy Submitted by AstraZeneca on 08/07/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/28/2019

Atezolizumab Submitted by Genentech, Inc. on 09/30/2019

Ramucirumab Submitted by Eli Lilly and Company on 10/29/2019

Atezolizumab Submitted by Genentech, Inc. on 12/03/2019

Guardant360 Submitted by Guardant Health, Inc. on 01/22/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Selpercatinib Submitted by Eli Lilly and Company on 03/27/2020

Guardant360 Submitted by Guardant Health, Inc. on 03/27/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/13/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 05/06/2020

Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020

Durvalumab Submitted by AstraZeneca on 05/14/2020

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/15/2020

Atezolizumab Submitted by Genentech, Inc. on 05/20/2020

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 05/26/2020

Brigatinib Submitted by Takeda Oncology on 05/26/2020

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 05/29/2020

Osimertinib Submitted by AstraZeneca on 05/31/2020

Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020

T-DXd Submitted by Daiichi Sankyo, Inc. on 06/15/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020

Key Recommendations Submitted by American Society for Radiation Oncology on 06/23/2020

Lenvatinib Submitted by Eisai Inc. on 06/23/2020

Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 06/30/2020

Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 07/01/2020

Guardant360 Submitted by Guardant Health, Inc. on 07/02/2020

Tumor Treating Fields Submitted by Novocure Inc. on 07/03/2020

Bevacizumab Submitted by Genentech, Inc. on 07/06/2020

Brigatinib Submitted by Takeda Oncology on 07/07/2020

Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 07/08/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 07/13/2020

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 08/08/2020

Pralsetinib Submitted by Blueprint Medicines Corporation on 09/08/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020

Osimertinib Submitted by AstraZeneca on 09/19/2020

Selpercatinib Submitted by Eli Lilly and Company on 09/21/2020

Atezolizumab Submitted by Genentech, Inc. on 10/01/2020

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 10/02/2020

Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 11/04/2020

Lorlatinib Submitted by Pfizer Inc. on 11/19/2020

Durvalumab Submitted by AstraZeneca Pharmaceuticals LP on 11/20/2020

Osimertinib Submitted by AstraZeneca on 12/21/2020

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 01/18/2021

Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 01/21/2021

Tepotinib Submitted by EMD Serono, Inc. on 02/04/2021

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/16/2021

Gene Expression Profiling (GEP) Submitted by bioTheranostics, Inc. on 06/10/2014

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/19/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020

Bevacizumab Submitted by Genentech on 03/10/2015

Bevacizumab Submitted by Genentech on 05/11/2010

Bevacizumab Submitted by Genentech on 06/10/2011

Bevacizumab Submitted by Genentech on 01/25/2012

Erlotinib Submitted by Genentech on 06/13/2012

Bevacizumab Submitted by Genentech on 06/22/2012

Doxorubicin Submitted by Oncology Analytics on 12/13/2012

Bevacizumab Submitted by Genentech on 10/11/2013

Olaparib Submitted by AstraZeneca on 12/22/2014

Bevacizumab Submitted by Genentech on 05/07/2015

Bevacizumab Submitted by Genentech on 10/01/2015

BRCA test Submitted by Ovarian Cancer National Alliance on 10/15/2015

Biomarker assays Submitted by Vermillion Inc. on 10/16/2015

ChemoFx® assay Submitted by Helomics on 10/21/2015

Genetic testing for BRCA status Submitted by Myriad Genetics Laboratories, Inc. on 10/23/2015

Olaparib Submitted by AztraZeneca on 09/13/2016

Trabectedin/docetaxel Submitted by Janssen Biotech on 09/30/2016

Multivariate index assay test OVA1 Submitted by Vermillion/ASPiRA Labs on 10/18/2016

Bevacizumab Submitted by Genentech on 12/07/2016

Rucaparib Submitted by Clovis Oncology on 12/20/2016

Niraparib Submitted by Tesaro on 04/11/2017

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Olaparib Submitted by AstraZeneca on 08/17/2017

Rucaparib Submitted by Clovis Oncology, Inc. on 09/19/2017

Next-generation sequencing (NGS) Submitted by Illumina Inc. on 10/09/2017

Homologous recombination deficiency (HRD) status Submitted by Myriad Genetic Laboratories, Inc. on 10/18/2017

Avelumab Submitted by EMD Serono, Inc. and Pfizer Inc. on 10/20/2017

OVA1/Multivariate Index Assay Submitted by Vermillion/AsPIRA Laboratories on 10/24/2017

Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 10/25/2017

Bevacizumab Submitted by Genentech, Inc. on 10/31/2017

PARP inhibitors Submitted by Tesaro, Inc. on 01/22/2018

Bevacizumab Submitted by Genentech, Inc. on 06/13/2018

Niraparib Submitted by Tesaro Inc. on 06/25/2018

PARP inhibitor maintenance Submitted by Tesaro Inc. on 10/10/2018

Niraparib Submitted by Tesaro Inc. on 10/12/2018

Olaparib Submitted by AstraZeneca on 10/22/2018

Olaparib Submitted by AstraZeneca on 06/03/2019

Olaparib Submitted by AstraZeneca on 07/02/2019

Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 07/26/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

OVA1/Multivariate Index Assay Submitted by Vermillion, Inc. on 09/18/2019

Bevacizumab-awwb Submitted by Tejas Patel, PharmD, BCOP United Healthcare on 09/26/2019

Nirabarib Submitted by GSK on 09/30/2019

Olaparib Submitted by AstraZeneca on 10/01/2019

Molecular testing Submitted by Foundation Medicine, Inc. on 10/02/2019

Trabectedin Submitted by Janssen Scientific Affairs on 02/04/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Olaparib Submitted by Clovis Oncology on 05/15/2020

Olaparib Submitted by AstraZeneca on 05/15/2020

Niraparib Submitted by GSK on 05/19/2020

Nivolumab Submitted by Bristol Myers Squibb on 06/04/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

myChoice CDx Submitted by Myriad Genetics Laboratories on 09/08/2020

OVA1 Multivariate Index Assay Submitted by ASPiRA Women’s Health on 09/10/2020

Guardant360 Submitted by Guardant Health on 09/11/2020

Lurbinectedin Submitted by Jazz Pharmaceuticals on 09/16/2020

TMB Submitted by Foundation Medicine, Inc. on 09/18/2020

CDx genomic profiling test Submitted by Foundation Medicine, Inc. on 11/06/2020

Interventional Radiologist (IR) consultation Submitted by Society of Interventional Oncology on 07/13/2020

Paclitaxel Submitted by Abraxis on 02/09/2010

Docetaxel Submitted by sanofi-aventis on 07/12/2010

Oxaliplatin Submitted by sanofi-aventis on 07/12/2010

Albumin-bound paclitaxel Submitted by Celgene Corporation on 08/21/2015

Familial/genetic risk assessment Submitted by Myriad Genetics Laboratories, Inc. on 08/21/2015

Irinotecan liposome injection Submitted by Merrimack Pharmaceuticals on 04/11/2016

Irreversible electroporation Submitted by AngioDynamics on 08/10/2016

Genetic testing Submitted by Myriad Genetic Laboratories, Inc. on 08/11/2016

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/03/2018

Olaparib Submitted by AstraZeneca on 06/02/2019

Olaparib Submitted by AstraZeneca on 06/02/2019

Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/25/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Evidence Blocks Submitted by United Healthcare on 02/24/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Germline testing Submitted by Myriad Genetics Laboratories, Inc. on 06/08/2020

Genomic profiling Submitted by Foundation Medicine, Inc. on 06/12/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Gemcitabine/albumin-bound paclitaxel/cisplatin Submitted by Dr. Dan Laheru on 06/18/2020

TMB Submitted by Foundation Medicine, Inc. on 06/22/2020

TMB Submitted by Foundation Medicine, Inc. on 09/15/2020

Blinatumomab Submitted by Amgen, Inc. on 02/11/2020

ClonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 05/22/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 10/15/2020

Fidaxomicin Submitted by Cubist Pharmaceuticals on 09/11/2014

Isavuconazonium sulfate Submitted by Astellas Pharma Global Development, Inc on 08/31/2016

Oritavancin Submitted by Global Health Science on 09/30/2016

Meropenem and Vaborbactam Submitted by Melinta Therapeutics, Inc. on 10/01/2018

Bezlotoxumab Submitted by Merck & Co. on 05/29/2019

Temp Traq Submitted by Blue Spark Technologies on 06/26/2019

Genetic Risk Assessment Submitted by Myriad on 09/21/2015

Family History Submitted by Myriad Genetic Laboratories, Inc. on 09/19/2016

SelectMDx Submitted by MDxHealth on 09/20/2016

3-gene expression assay Submitted by Exosome Diagnostics, Inc. on 01/04/2017

Family History Submitted by Myriad Genetic Laboratories, Inc. on 08/02/2017

3-gene expression assay Submitted by Exosome Diagnostics, Inc on 01/05/2018

EPI biomarker Submitted by Exosome Diagnostics, Inc on 04/23/2018

3-gene expression assay Submitted by Exosome Diagnostics, Inc on 08/13/2018

EPI test Submitted by Exosome Diagnostics, Inc on 09/20/2018

SelectMDx Submitted by MDxHealth on 10/02/2018

SelectMDx Submitted by MDxHealth on 06/03/2019

Germline Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 09/18/2020

miR Scientific Sentinel Prostate Cancer Test Platform Submitted by Columbia University Medical Center on 09/23/2020

miR Scientific Sentinel™ Prostate Cancer Test Platform Submitted by miR Scientific on 09/29/2020

Sipuleucel-T Submitted by Dendreon Corporation on 05/03/2010

Abiraterone Acetate Submitted by Centocor Ortho Biotech on 04/28/2011

Sipuleucel-T Submitted by Dendreon Corporation on 07/25/2011

Degarelix Submitted by Ferring Pharmaceuticals on 08/22/2011

Degarelix Submitted by Ferring Pharmaceuticals on 11/01/2011

Denosumab Submitted by Amgen on 03/30/2012

Abiraterone Acetate Submitted by Janssen Biotech on 12/10/2012

Radium Ra 223 Dichloride Submitted by Bayer Healthcare Pharmaceuticals on 05/16/2013

Enzalutamide Submitted by Astellas Scientific on 03/27/2014

Molecular Assays Submitted by Myriad on 05/16/2014

Docetaxel in combination with androgen deprivation therapy (ADT) Submitted by Sanofi on 06/03/2014

Cellsearch Submitted by Janssen Diagnostics, LLC on 04/24/2015

ProMark Submitted by Johns Hopkins Medical Insitutions on 05/01/2015

Decipher® Prostate Cancer Classifier Submitted by GenomeDx Biosciences Inc. on 05/12/2015

Oncotype DX Prostate Cancer Assay Submitted by Genomic Health Inc. on 05/29/2015

Enzalutamide Submitted by Astellas Pharma on 06/02/2015

Enzalutamide Submitted by Astellas Pharma on 03/01/2016

Enzalutamide Submitted by Astellas Pharma on 05/03/2016

22-marker genomic classifier (GC) tumor tissue-based molecular assay Submitted by GenomeDx Biosciences Inc. on 05/26/2016

Genetic risk assessment/testing Submitted by Myriad Genetic Laboratories, Inc. on 05/27/2016

PET/CT Imaging Submitted by Medical Imaging & Technology Alliance on 05/27/2016

PET Imaging Submitted by Blue Earth Diagnostics, Inc. on 05/27/2016

PTEN status Submitted by Eastern Virginia Medical School on 06/09/2016

Uridine triacetate Submitted by Wellstat Therapeutics on 08/16/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Active Surveillance Submitted by Prostate Cancer Patient Education and Advocacy Organizations on 05/31/2017

Tissue-based molecular assay Submitted by GenomeDx Biosciences Inc. on 06/01/2017

Tumor-based molecular assays Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2017

Abiraterone acetate Submitted by Janssen Scientific Affairs, LLC on 06/08/2017

Abiraterone Acetate Submitted by Kansas City Urology Care on 12/07/2017

Apalutamide Submitted by Janssen Scientific Affairs, LLC on 02/15/2018

Enzalutamide Submitted by Astellas Pharma Inc. on 03/15/2018

Apalutamide Submitted by Janssen Scientific Affairs, LLC on 05/23/2018

Genomic classifier Submitted by GenomeDx Biosciences Inc. on 06/01/2018

Fluciclovine Submitted by Blue Earth Diagnostics, Inc. on 06/06/2018

AR-V7 Submitted by Epic Sciences, Inc. on 06/07/2018

Prolaris Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018

Prolaris Post‐RP Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018

Denosumab and Zolendronic Acid Submitted by Prostate Health Education Network, Inc. on 06/20/2018

Enzalutamide Submitted by Astellas Pharma on 07/13/2018

GnRH antagonist degarelix Submitted by Ferring Pharmaceuticals on 10/11/2018

Abiraterone Acetate Submitted by Value in Cancer Care Consortium (ViC3) on 10/14/2018

Sipuleucel-T Submitted by Dendreon Pharmaceuticals LLC on 02/19/2019

Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 03/15/2019

Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 04/09/2019

Tumor Tissue-Based Molecular Assay Submitted by Decipher Biosciences Inc. on 06/01/2019

Apalutamide Submitted by Janssen Scientific Affairs, LLC on 06/04/2019

Molecular and biomarker analysis of tumor Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019

Genetic Testing in Active Surveillance Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019

Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019

PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/06/2019

Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 06/11/2019

Enzalutamide Submitted by Astellas Pharma Global Development, Inc. on 07/29/2019

Olaparib Submitted by AstraZeneca on 09/30/2019

Cabazitaxel Submitted by Sanofi on 10/08/2019

Atezolizumab Submitted by Genentech, Inc. on 11/27/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Cabazitaxel Submitted by Sanofi on 03/23/2020

Guardant360 Submitted by Guardant Health, Inc. on 04/22/2020

Molecular/Biomarker Analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020

Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020

Genomic profiling Submitted by Foundation Medicine, Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Cabazitaxel Submitted by Sanofi on 05/04/2020

Darolutamide Submitted by Bayer Healthcare Pharmaceuticals on 05/11/2020

Rucaparib Submitted by Clovis Oncology, Inc. on 05/15/2020

Rucaparib Submitted by Clovis Oncology, Inc. on 05/15/2020

Relugolix Submitted by Myovant Sciences, Inc. on 12/23/2020

18F-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography (FGD PET/CT) Submitted by Medical Imaging & Technology Alliance on 03/31/2014

Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2016

Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2018

Atezolizumab Submitted by Genentech, Inc. on 09/25/2018

Nivolumab Submitted by Bristol-Myers Squibb Company on 04/11/2019

Entrectinib Submitted by Genentech, Inc. on 08/15/2019

Durvalumab Submitted by AstraZeneca Pharmaceuticals on 09/19/2019

Nivolumab Submitted by Bristol-Myers Squibb Company on 12/04/2019

Atezolizumab Submitted by Genentech, Inc. on 12/23/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Lurbinectedin Submitted by Jazz Pharmaceuticals on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Lurbinectedin Submitted by Jazz Pharmaceuticals on 06/15/2020

Nivolumab Submitted by Bristol-Myers Squibb Company on 12/29/2020

Trilaciclib Submitted by G1 Therapeutics on 02/12/2021

Pembrolizumab Submitted by Merck & Co., Inc. on 03/31/2021

Vaping/E-Cigarettes Submitted by Robert B. Sklaroff MD on 11/23/2015

Vaping/E-Cigarettes Submitted by Robert B. Sklaroff MD on 07/11/2016

Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 10/03/2012

Diagnostic Algortihm Submitted by The Life Raft Group on 05/21/2019

ENLIVEN, pexidartinib Submitted by Daiichi-Sankyo on 08/05/2019

Entrectinib Submitted by Genentech, Inc. on 08/16/2019

Avapritinib Submitted by Blueprint Medicines Corporation on 01/07/2020

Avapritinib Submitted by Blueprint Medicines Corporation on 01/09/2020

Tazemetostat Submitted by Epizyme Inc. on 01/23/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020

Treatment Algorithm Submitted by The Desmoid Tumor Research Foundation on 03/17/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Ripretinib Submitted by Deciphera Pharmaceuticals on 05/18/2020

Footnotes Submitted by Society of Interventional Oncology on 06/08/2020

Cabozantinib Submitted by Exelixis, Inc. on 06/10/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 06/17/2020

Ripretinib Submitted by Deciphera Pharmaceuticals on 06/19/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/23/2020

Ripretinib Submitted by Deciphera Pharmaceuticals on 08/17/2020

Genetic risk assessment/testing Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2015

Bioimpedance spectroscopy (L-Dex U400) Submitted by ImpediMed, Inc. on 10/28/2015

Genetic risk assessment Submitted by Myriad Genetic Laboratories, Inc. on 10/10/2016

Naloxegol Submitted by AstraZeneca/Medical Affairs on 10/04/2017

Lymphedema symptom assessment Submitted by Vanderbilt University School of Nursing on 10/31/2018

LGBTQ Resources Submitted by Tanya Fischer on 04/18/2019

Genetic risk assessment and testing Submitted by Myriad Genetic Laboratories on 10/29/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2017

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 05/30/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/07/2017

Ibrutinib Submitted by Pharmacyclics LLC on 09/29/2017

Defibrotide Submitted by Jazz Pharmaceuticals on 11/17/2017

Next-generation sequencing (NGS) Submitted by Illumina Inc. on 05/07/2018

Next generation sequence based analysis Submitted by Adaptive Biotechnologies on 05/18/2018

Mogamulizumab Submitted by Kyowa Kirin, Inc. on 07/30/2018

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 11/21/2018

Duvelisib Submitted by Verastem, Inc. on 05/17/2019

Duvelisib + Romidepsin Submitted by Verastem, Inc. on 05/17/2019

Next-generation sequencing (NGS) Submitted by Adaptive Biotechnologies Corporation on 06/28/2019

Pembrolizumab Submitted by Merck & Co., Inc. on 02/03/2020

Duvelisib Submitted by Verastem, Inc. on 06/11/2020

Leucovorin Submitted by Acrotech Biopharma, LLC on 06/12/2020

ENKTL Submitted by Sun Yat-sen University Cancer Center on 06/14/2020

clonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 06/19/2020

Pembrolizumab Submitted by Merck & Co. on 05/31/2017

BEP x 3 Submitted by Indiana University Simon Cancer Center on 03/05/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Sorafenib Submitted by Bayer HealthCare Pharmaceuticals and Onxy Pharmaceuticals, Inc. on 06/26/2013

Lenvatinib Submitted by Eisai Inc. on 02/25/2015

Everolimus in combination with Sorafenib Submitted by Novartis Pharmaceuticals Corporation on 10/16/2015

Lenvatinib Submitted by Eisai Inc. on 10/27/2017

Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 01/09/2018

Thyrotropin alfa Submitted by Sanofi US on 08/31/2018

Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 10/15/2018

Thyrotropin alfa Submitted by Sanofi US on 04/22/2019

Entrectinib Submitted by Genentech, Inc. on 08/16/2019

Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020

Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/29/2020

Pralsetinib Submitted by Blueprint Medicines Corporation on 12/01/2020